The ASXL1 Knockout HeLa Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population in which the ASXL1 gene has been disrupted to create a loss-of-function model. This genetically heterogeneous pool captures a range of editing events, enabling robust and reproducible functional studies without the phenotypic bottlenecks associated with monoclonal derivation. The polyclonal format is particularly suited for transient and stable knockout experiments where population-level responses are critical.
Derived from the HeLa cell line, these cells retain the characteristics of human cervical adenocarcinoma: they are HPV-18 positive, express wild-type p53, and exhibit continuous telomerase activity. HeLa cells are a cornerstone in cancer biology, widely employed for mechanistic studies in signal transduction, virology, and drug response. Their epithelial origin and well-characterized genomic landscape make them an ideal host for investigating the impact of chromatin and transcription factor disruptions.
ASXL1 encodes a chromatin-binding scaffold protein that orchestrates histone modification and transcriptional activation. It serves as the regulatory subunit of the PR-DUB complex, directly interacting with the deubiquitinase BAP1 to remove monoubiquitination from lysine 119 of histone H2A (H2AK119ub), a mark deposited by PRC1. This activity counteracts Polycomb-mediated gene silencing at loci such as HOX clusters. Additionally, ASXL1 acts as a transcriptional coactivator for retinoic acid receptors, forming complexes with RAR?? and calreticulin (CALR) to drive expression of retinoic acid-responsive genes. Upstream regulators include retinoic acid, RAR/RXR heterodimers, and transcription factors E2F1 and SP1. Downstream targets span p16INK4a, cyclin-dependent kinase inhibitors, PU.1, and C/EBP??, linking ASXL1 to cell cycle control and myeloid differentiation. Interacting factors also include EZH2 and SUZ12, underscoring its integration into Polycomb repressive networks.
In the HeLa cervical cancer model, ASXL1 knockout provides a powerful system to dissect its epigenetic and transcriptional roles independent of hematopoietic context. While ASXL1 mutations are prominent in myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia, ASXL1 also exhibits tumor-suppressive functions in colorectal cancer and is mutated in the developmental disorder Bohring-Opitz syndrome. Disrupting ASXL1 in HeLa cells allows researchers to examine conserved mechanisms of polycomb regulation, retinoic acid signaling, and chromatin remodeling in an epithelial solid tumor background, offering insights into cancer epigenetics beyond hematological malignancies.
These polyclonal knockout cells enable a broad array of experimental applications, including mechanistic studies of epigenetic regulation in cancer, modeling of ASXL1-mutant pathologies, and drug screening for targeted therapies. Representative assays include Western blotting for ASXL1 protein loss, RT-qPCR for downstream target expression (e.g., HOX genes, PU.1, C/EBP??), ChIP-qPCR to monitor H2AK119ub levels, and co-immunoprecipitation to confirm BAP1 interaction. Functional assays such as cell viability, colony formation, and migration further characterize the knockout phenotype, while transcriptomic profiling via RNA-seq reveals global regulatory changes. For more information, please contact Ascent Research.
